CleanCore Solutions 株価情報 (AMEX: ZONE)

最新ニュース CleanCore Solutions (AMEX:ZONE) 株価情報

CleanCore Solutions

CleanCore Solutions Inc engages in the development and manufacturing of cleaning products that produce pure aqueous ozone for professional, industrial, or home use. The firm has a patented nanobubble technology using aqueous ozone that is effective in cleaning, sanitizing, and deodorizing surfaces and high-touch areas. The company offers products and solutions that are marketed for janitorial and sanitation, ice machine cleaning, laundry, and industrial industries. Its products are used in many types of environments including retail establishments, distribution centers, factories, warehouses, restaurants, schools and universities, airports, healthcare, food service, and commercial buildings such as offices, malls, and stores.

CleanCore Solutions Inc. Class B Common Stock

CleanCore Solutions Inc

ZONED PROPERTIES INC by Zoned Properties, Inc.

Zoned Properties Inc

Zonetail Inc

Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading lower on Friday</a>.
On Thursday, the company reported first-quarter earnings per share of 35 cents loss, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45454254/sidus-space-reports-first-quarter-2025-financial-results-and-provides-business-update" rel="noreferrer noopener">up from $(1.40) loss a year ago</a>.
Sidus Space reported first quarter revenue of $238,000, down from $1.05 million a year ago. The decline reflects a shift from legacy services to new commercial models.
Sidus Space posted a gross loss of $1.6 million in Q1, compared to a $84,000 profit last year, as high-margin legacy services declined.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/space/25/04/44720625/sidus-space-reflex-aerospace-launch-global-satellite-venture" rel="noreferrer noopener">Sidus Space, Reflex Aerospace Launch Global Satellite Venture</a>
Adjusted EBITDA loss widened to $4.7 million from $2.7 million, while cash rose to $11.7 million from $6.2 million year-over-year.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, SIDU stock has lost over 50% in the past year.
On Thursday, the company announced the successful on-orbit deployment and operation of its second-generation edge computing device, FeatherEdge GEN-2, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45465978/sidus-space-announces-successful-on-orbit-operation-of-featheredge-gen-2-aboard-lizziesat-3" rel="noreferrer noopener">onboard the LizzieSat-3 spacecraft</a>.
With this milestone, FeatherEdge GEN-2 has achieved flight-proven status and is now being offered commercially as a space-hardened AI processing platform.
The advanced computer, built around NVIDIA&#8217;s Jetson Orin NX, delivers 100 trillion operations per second (TOPS) of artificial intelligence capability. Engineered for resilience in radiation-intense environments, FeatherEdge GEN-2 is designed to handle real-time processing tasks in low Earth orbit.
&#8220;What sets this technology apart is its broad market applicability,&#8221; said Carol Craig, CEO of Sidus Space.
&#8220;While designed for space, FeatherEdge GEN-2 has the potential to drive revenue across multiple domains—including defense, intelligence, maritime, aviation, and terrestrial remote sensing—by enabling near real-time data processing at the edge,&#8221; Craig added.
Price Action: SIDU shares are trading lower by 9.67% to $1.64 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45470155/consumer-sentiment-crashes-to-5-year-lows-as-inflation-fears-reach-1981-levels" target="_blank" rel="noreferrer noopener">Consumer Sentiment Crashes To 5-Year Lows As Inflation Fears Reach 1981 Levels</a></li>
</ul>
Image: Shutterstock

Equities

News

Markets

Movers

General

SIDU

Why Is Sidus Space Stock Falling Today?

B. Riley Securities analyst Harold Goetsch maintains Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) with a Buy and raises the price target from $4.7 to $5.5.

Price Target

Analyst Ratings

B. Riley Securities Maintains Buy on Bitcoin Depot, Raises Price Target to $5.5

B. Riley Securities analyst Randy Binner reiterates Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) with a Buy and raises the price target from $12 to $13.

Reiteration

AOMR

B. Riley Securities Reiterates Buy on Angel Oak Mortgage REIT, Raises Price Target to $13

Benchmark analyst Fawne Jiang maintained Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) with a Buy and lowered the <a target="_blank" href="https://www.benzinga.com/quote/BABA/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$190&nbsp;to&nbsp;$176</a> on Friday.
Alibaba reported its <a href="https://www.benzinga.com/news/earnings/25/05/45437447/alibaba-stock-slides-5-after-revenue-miss-cloud-spend-hits-free-cash-flow" target="_blank" rel="noreferrer noopener">fiscal fourth-quarter</a> revenue growth of 7% to $32.58 billion, missing the analyst consensus estimate of $33.08 billion. It clocked an adjusted earnings per ADS of $1.73, which beat the analyst consensus estimate of $1.48. 
Also Read: <a href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs" target="_blank" rel="noreferrer noopener">US Listed Chinese Stocks Rally As Countries Agree To Ease Import Tariffs</a>
Revenue from Taobao and Tmall Group grew by 9% to $13.97 billion. Revenue from Alibaba International Digital Commerce Group increased by 22% to $4.63 billion, driven by the growth of cross-border businesses. In addition:
<ul class="wp-block-list">
<li>Local Services Group revenue grew by 10% to $2.22 billion</li>
<li>Orders for Amap and Ele.me grew </li>
<li>Cainiao Smart Logistics Network Limited's revenue decreased 12% to $2.97 billion.</li>
<li>Cloud Intelligence Group revenue grew by&nbsp;18%&nbsp;to&nbsp;$4.15 billion.</li>
<li>Digital Media and Entertainment Group rose&nbsp;12%&nbsp;to&nbsp;$765 million.</li>
<li>Customer management revenue (CMR) grew 12%</li>
<li>Cloud revenue accelerated to high teens, fueled by strong demand for AI services.</li>
</ul>
Jiang blamed Alibaba International Digital Commerce Group&#8217;s soft performance and outdated consensus estimates.
Looking ahead, Jiang expects CMR to continue outpacing GMV growth through fiscal 2026, supported by sustained take rate gains, and Cloud to maintain momentum with new customer onboarding and cross-selling. AIDC growth may moderate amid evolving global trade dynamics. At the same time, Ele.me ramps up investment in food delivery and instant commerce in partnership with Taobao and Tmall Group to defend against JD.com, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) and offensively drive engagement via Taobao app integration.
Jiang raised his revenue projections for CMR and TTG but lowered the group-level growth forecast to 6% (from 11% previously, excluding asset divestitures), reflecting AIDC resets and potential headwinds from Ele.me.
While the fiscal fourth quarter was not clean, and near-term margin pressure remains a concern, the analyst continues to view Alibaba as a leading beneficiary of accelerated AI adoption in China and a top structural player in the sector.
Jiang projected fiscal 2026 revenue of $134.44 billion and EPS of $8.50. He expects fiscal 2027 revenue of $146.03 billion and EPS of $11.01.
Price Action:&nbsp;BABA shares traded higher by&nbsp;0.64%&nbsp;at&nbsp;$124.69 at&nbsp;the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45443398/zeekr-vehicle-sales-jump-25-cost-cuts-drive-record-margins" target="_blank" rel="noreferrer noopener">Zeekr Vehicle Sales Jump 25%, Cost Cuts Drive Record Margins</a></li>
</ul>
Image: Shutterstock

Trading Ideas

BABA

Alibaba Misses Revenue, But AI Cloud Has Silver Lining

FST (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBSX#NASDAQ">KBSX</a>) reported quarterly losses of $(0.09) per share. This is a 80 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $36.50 million in sales this quarter. This is a 27.04 percent increase over sales of $28.73 million the same period last year.

Earnings

KBSX

FST FY EPS $(0.09) Down From $(0.05) YoY, Sales $36.50M Up From $28.73M YoY

On May 12, President Donald Trump followed through on a campaign promise by signing an Executive Order (EO) mandating that pharmaceutical companies lower their prescription drug prices in the US to those seen abroad.
At a media event, Trump told reporters he was aiming for price cuts of between 59% and 90% and gave drug companies 30 days to play ball.
Wall Street digested the news, and while major biopharma stocks saw share prices drop the day the EO was announced, most industry stocks rebounded.&nbsp;
Here are three pharma stocks that won&#8217;t just rebound, but are poised to soar because of Trump&#8217;s executive order.
<h1 class="wp-block-heading">Team Trump on Solid Ground?</h1>
Nobody&#8217;s denying that US drug prices are out of whack. A 2024 RAND Corporation study concluded US drug prices were approximately three times higher than those in 33 other developed countries.
Presidents have full power to order such a price cut from a private industry, at least in part.
&#8220;That&#8217;s especially the case in sectors like healthcare where government programs like Medicare are massive buyers,&#8221; said Lou Carter, founder and CEO at the Best Practice Institute in Palm Beach Gardens, Fla. &#8220;Policy isn&#8217;t just about law—it&#8217;s about leverage. This EO uses the weight of public programs to force pricing accountability, and that&#8217;s smart business when you&#8217;re managing taxpayer funds.&#8221;
Congress and the courts can try to stop the EO in its tracks, but success on that front is unlikely.&nbsp;
&#8220;Politically, it&#8217;s tough to argue against lower drug prices,&#8221; Carter said. &#8220;Even if pharma lobbies hard, most lawmakers know it&#8217;s political suicide to oppose something that helps seniors afford insulin. If this goes to court, it&#8217;ll hinge on procedural questions—not on whether the move is popular or right.&#8221;
<h1 class="wp-block-heading">Bigger Drug Makers are Hardest Hit</h1>
Given the size and scope of the EO, it&#8217;s no surprise that the more substantial drug companies may find themselves in financial trouble.&nbsp;
&#8220;Large-cap biotech and specialty pharma companies with heavy Medicare exposure like Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) or Regeneron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) could be hit hardest,&#8221; said Dr. Will Soliman, Founder and CEO of the New York City-based Accreditation Council for Medical Affairs. &#8220;They rely on high-margin (Medicare) Part B drugs.&#8221;
Vertical-oriented drug makers could also feel the heat from the EO.&nbsp;
&#8220;Specialized oncology manufacturers like Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) have greater exposure than diversified pharmaceutical companies with broader portfolio ranges,&#8221; said Seann Malloy, founder and managing partner of Malloy Law Offices in Bethesda, Md. &#8220;Small to mid-cap biotechnology companies with early commercial products often fall outside immediate impact zones due to limited Medicare utilization and existing price protection provisions. &#8220;
&#8220;The executive order&#8217;s key element mandates that Medicare&#8217;s prescription drug payments align with the lowest prices in other developed countries, essentially using international reference pricing,&#8221; Malloy said. &#8220;While some demonstration projects will start within 30 days, full implementation across all provisions will take longer, likely 6-12 months, due to necessary regulatory development. &#8220;
Timing could play a big role in determining how much of an impact the EO will have on biotech drug stocks, if any.
Initially, the order focuses on physician-administered drugs under Medicare Part B but may later include retail prescriptions under Part D. &#8220;This staged implementation means the immediate and long-term market effects will differ, a point often missed by investors,&#8221; Malloy noted. &#8220;Despite initial impressions of swift price changes, significant revenue impacts will likely be delayed by extensive regulatory procedures.&#8221;
Additionally, overseas drug providers may face stiff headwinds from the Trump drug price directive.
&#8220;International manufacturers are most vulnerable,&#8221; said Javier Palomarez, founder and CEO of the United States Hispanic Business Council. &#8220;Many of them ship to the United States because of the return on investment &#8211; eroding that return dampens the incentive and ability to ship medicines across the world, which could lead to total loss of US market access for some companies.&#8221;
<h1 class="wp-block-heading">Three Drug Stocks That Bear Watching Over the Next 30 Days</h1>
Biotech investors looking to leverage the Trump EO should understand Trump&#8217;s intention to &#8220;cut out the middleman,&#8221; as he said in his May 12 press event. This translates to good news for actual drug manufacturers and not-so-good news for so-called pharmacy-benefit managers.
PBM&#8217;s act as intermediaries between health insurance companies, big employers, drug manufacturers, insurers, and patients. While they don&#8217;t produce prescription drugs, they handle the more mundane side of the drug business, like claims processing and negotiating prescription drug prices.
The big drug producers have historically blamed the PBMs for sky-high drug prices and would likely back any initiative that expands the direct-to-consumer drug marketplace. In that scenario, no insurers are needed, as drug consumers could deal directly with drug manufacturers to buy the medicines they need, presumably at a more affordable price.
Investors in that marketplace would want large drug makers, and big PBMs would not. These three drug stocks stand out on the plus side.
<h2 class="wp-block-heading">Eli Lilly</h2>
Drug manufacturing giant Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is priced high at $730 per share, but it&#8217;s a stock that would likely prosper in a direct-to-consumer prescription drug marketplace. The stock is off by 5.0% year-to-date, but 26 Wall Street analysts who track LLY give it a top rating. The company&#8217;s recent earnings per share are off the charts, with an upward spike of 106% in EPS in 2024 and an estimated 68% in 2025. The stock is off 20% compared to recent highs, which could mean a nice discount for a drug industry stalwart.
<h2 class="wp-block-heading">Novo Nordisk</h2>
Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has experienced market woes that preceded the Trump E/O, as competitors continue to chew into market share in the lucrative weight loss drug market. Particularly damaging was a recent study that concluded patients taking Eli Lilly&#8217;s Zepbound were losing weight faster than with Novo&#8217;s Wegovy. That&#8217;s one big reason Novo Nordisk has seen its share price fall by 50% over the past year. Yet the stock is in rebound mode right now, up 13.9% over the past month. A $2.2 billion deal between Novo and Septerna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) to develop weight loss pills is seen as a big step by analysts and big names like Goldman Sachs and JP Morgan are sticking to their buy calls on the stock. Meanwhile, a larger group of industry analysts is out with a consensus 50% share price upside from current levels.
<h2 class="wp-block-heading">AbbVie</h2>
AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is a genuine cash flow producer that seems immune to any political interference from Washington, D.C. The drug manufacturer has a diverse set of popular prescription drugs, like Botox, Humira, Rinvoq, and Skyrizi. The stock only fell by a paltry 1% on the E news this week, and is up 5% over the past month. It also comes with a healthy 3.6% dividend for income-minded investors, a robust drug pipeline in play, and a brand new regulatory &#8220;green light&#8221; for its lung cancer drug Emrelis, supporting the rationale that ABBV shares should continue to climb in 2025.
<a href="https://benzinga.zoom.us/webinar/register/WN_OJ2FBspHSJSSVNlW8zGapw/?utm_campaign=webinar052025&amp;utm_adType=sponsorad&amp;utm_ad=RD051925/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter">Smart Options Plays for Traders Watching Junk Bonds</a> Credit markets are breaking down. Volatility is back. Join Ryan Faloona, Anne-Marie Baiynd, and Tim Melvin live on May 20 at 6 PM ET to see how seasoned traders are using junk bond signals and short-term options to hedge, profit, and stay a step ahead. <a href="https://benzinga.zoom.us/webinar/register/WN_OJ2FBspHSJSSVNlW8zGapw/?utm_campaign=webinar052025&amp;utm_adType=sponsorad&amp;utm_ad=RD051925/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter">Save your seat for this live tactical session.</a>
Image via Shutterstock

Opinion

ABBV

AMGN

REGN

SEPN

3 Stocks That Will Profit From Trump's Drug Price Cut

<h3>Gainers</h3>
<ul>
<li>Lazydays Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) stock increased by 67.6% to $0.23 during Friday's regular session. The market value of their outstanding shares is at $25.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>Amesite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) stock rose 44.64% to $3.24. The market value of their outstanding shares is at $12.9 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares rose 34.12% to $1.69. The market value of their outstanding shares is at $483.6 million. </li>
<li>Ruanyun Edai Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) stock increased by 28.58% to $10.03. The company's market cap stands at $338.5 million. </li>
<li>PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) stock rose 27.77% to $1.5. The market value of their outstanding shares is at $140.1 million. The company's, Q1 earnings came out yesterday. </li>
<li>Epsium Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSM#NASDAQ">EPSM</a>) shares moved upwards by 11.98% to $14.67. The company's market cap stands at $197.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Netclass Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) stock declined by 29.0% to $13.6 during Friday's regular session. The company's market cap stands at $242.4 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares decreased by 16.57% to $0.1. The market value of their outstanding shares is at $40.4 million. </li>
<li>YSX Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YSXT#NASDAQ">YSXT</a>) stock decreased by 14.76% to $5.2. The market value of their outstanding shares is at $121.8 million. </li>
<li>Newegg Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) stock decreased by 13.75% to $6.4. The company's market cap stands at $124.6 million. </li>
<li>REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) shares decreased by 12.71% to $0.81. The market value of their outstanding shares is at $22.8 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGB#NASDAQ">QVCGB</a>) stock fell 12.58% to $4.97. The company's market cap stands at $2.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMST

EPSM

GORV

NEGG

NTCL

NWTN

PLBY

QVCGA

QVCGB

RYET

YSXT

12 Consumer Discretionary Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) stock moved upwards by 178.2% to $3.95 during Friday's regular session. The company's market cap stands at $253.7 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock increased by 26.52% to $0.72. The company's market cap stands at $24.2 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) shares increased by 25.62% to $22.11. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 25.47% to $0.28. The company's market cap stands at $40.0 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock moved upwards by 25.33% to $1.88. The company's market cap stands at $94.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 22.8% to $5.43. The market value of their outstanding shares is at $3.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 67.3% to $0.01 during Friday's regular session. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 22.48% to $0.01. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 19.63% to $0.65. The company's, Q2 earnings came out yesterday. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 18.92% to $0.04. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock declined by 18.44% to $3.15. The company's market cap stands at $33.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock declined by 18.15% to $2.12. The company's market cap stands at $13.0 million. As per the press release, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACAD

APDN

ATPC

AYTU

BDSX

HCTI

INZY

LTRN

NCNA

PLRZ

RANI

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Virgin Galactic Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) stock moved upwards by 79.5% to $6.01 during Friday's regular session. The market value of their outstanding shares is at $245.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) stock increased by 24.4% to $2.6. The market value of their outstanding shares is at $56.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) shares increased by 23.03% to $6.89. The company's market cap stands at $344.8 million. </li>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) stock rose 19.77% to $6.36. The company's market cap stands at $3.8 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares rose 17.47% to $0.16. The company's market cap stands at $4.6 million. </li>
<li>Tecogen (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TGEN#AMEX">TGEN</a>) stock rose 17.36% to $4.12. The company's market cap stands at $102.9 million. As per the press release, Q1 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Click Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) shares decreased by 30.6% to $0.49 during Friday's regular session. The market value of their outstanding shares is at $15.5 million. </li>
<li>ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) stock fell 17.97% to $2.1. The company's market cap stands at $24.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) shares decreased by 17.08% to $0.92. The market value of their outstanding shares is at $2.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>SUNation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) stock fell 13.42% to $1.77. The company's market cap stands at $5.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>KULR Technology Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) stock fell 12.96% to $1.29. The company's market cap stands at $308.2 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Beam Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) shares fell 12.6% to $1.72. The market value of their outstanding shares is at $26.6 million. As per the news, the Q1 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BEEM

CLIK

ELPW

KULR

LICN

NVVE

SPCE

SUNE

TGEN

VSTE

12 Industrials Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) stock rose 76.1% to $15.62 during Friday's regular session. The market value of their outstanding shares is at $351.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) stock moved upwards by 32.57% to $12.25. The market value of their outstanding shares is at $1.6 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) stock moved upwards by 30.75% to $1.4. The market value of their outstanding shares is at $97.0 million. </li>
<li>Cemtrex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) stock increased by 28.12% to $2.46. The company's market cap stands at $4.3 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) shares increased by 26.19% to $5.3. The market value of their outstanding shares is at $866.3 million. </li>
<li>CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) shares rose 23.43% to $81.18. The market value of their outstanding shares is at $37.7 billion. As per the press release, Q1 earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Zenvia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENV#NASDAQ">ZENV</a>) stock declined by 27.6% to $1.34 during Friday's regular session. The market value of their outstanding shares is at $69.5 million. </li>
<li>Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) shares fell 25.1% to $99.5. The market value of their outstanding shares is at $4.3 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>ReAlpha Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) stock decreased by 19.72% to $0.56. The market value of their outstanding shares is at $25.8 million. As per the press release, Q1 earnings came out today. </li>
<li>WidePoint (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WYY#AMEX">WYY</a>) stock fell 19.25% to $4.28. The company's market cap stands at $41.8 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) stock declined by 18.71% to $2.06. The company's market cap stands at $14.4 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares declined by 15.6% to $1.51. The market value of their outstanding shares is at $15.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRE

CETX

CRWV

EVLV

GLOB

GRYP

MLGO

Next Technology Holding Inc. - Ordinary Shares

NXTT

QUBT

TSSI

ZENV

12 Information Technology Stocks Moving In Friday's Intraday Session

WIIM

GMED

Globus Medical shares are trading higher after the company announced a $500 million share repurchase program.

Investors with a lot of money to spend have taken a bearish stance on Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ORCL, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 12 options trades for Oracle.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $39,590, and 11, calls, for a total amount of $1,498,120.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $110.0 to $230.0 for Oracle during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Oracle's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Oracle's significant trades, within a strike price range of $110.0 to $230.0, over the past month.
<h3>Oracle Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747414995_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$14.8</td>
<td>$13.85</td>
<td>$14.76</td>
<td>$145.00</td>
<td>$626.2K</td>
<td>4.2K</td>
<td>1.2K</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$14.5</td>
<td>$14.45</td>
<td>$14.45</td>
<td>$155.00</td>
<td>$323.9K</td>
<td>519</td>
<td>1.1K</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$15.3</td>
<td>$14.45</td>
<td>$14.49</td>
<td>$155.00</td>
<td>$172.0K</td>
<td>519</td>
<td>957</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$10.3</td>
<td>$10.1</td>
<td>$10.3</td>
<td>$160.00</td>
<td>$103.0K</td>
<td>1.4K</td>
<td>100</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$14.9</td>
<td>$14.3</td>
<td>$14.43</td>
<td>$155.00</td>
<td>$67.8K</td>
<td>519</td>
<td>62</td>
</tr>
</tbody>
</table>

<h3>About Oracle</h3>
Oracle provides enterprise applications and infrastructure offerings around the world through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used for running online transaction processing and data warehousing workloads. Besides database systems, Oracle also sells enterprise resource planning, or ERP, customer relationship management, or CRM, and human capital management, or HCM, applications. Today, Oracle has more than 159,000 full-time employees in over 170 countries.
Having examined the options trading patterns of Oracle, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Oracle</h3>
<ul>
<li>With a volume of 2,989,890, the price of ORCL is up 0.13% at $159.61. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 25 days.</li>
</ul>
<h3>Expert Opinions on Oracle</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $130.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler downgraded its action to Neutral with a price target of $130. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Oracle options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

ORCL

Decoding Oracle's Options Activity: What's the Big Picture?

Financial giants have made a conspicuous bullish move on Chipotle Mexican Grill. Our analysis of options history for Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) revealed 13 unusual trades.
Delving into the details, we found 53% of traders were bullish, while 46% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $617,604, and 3 were calls, valued at $83,903.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $54.0 and $55.0 for Chipotle Mexican Grill, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Chipotle Mexican Grill's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Chipotle Mexican Grill's whale trades within a strike price range from $54.0 to $55.0 in the last 30 days. 
<h3>Chipotle Mexican Grill Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747414989_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$4.35</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$55.00</td>
<td>$84.0K</td>
<td>3.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CMG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$4.35</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$55.00</td>
<td>$73.0K</td>
<td>3.9K</td>
<td>848</td>
</tr>
<tr>
<td>CMG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.55</td>
<td>$4.25</td>
<td>$4.55</td>
<td>$55.00</td>
<td>$68.2K</td>
<td>3.9K</td>
<td>300</td>
</tr>
<tr>
<td>CMG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.5</td>
<td>$4.35</td>
<td>$4.5</td>
<td>$55.00</td>
<td>$67.4K</td>
<td>3.9K</td>
<td>450</td>
</tr>
<tr>
<td>CMG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.4</td>
<td>$4.35</td>
<td>$4.4</td>
<td>$55.00</td>
<td>$66.0K</td>
<td>3.9K</td>
<td>150</td>
</tr>
</tbody>
</table>

<h3>About Chipotle Mexican Grill</h3>
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $11.3 billion in 2024. The Mexican concept is almost exclusively company-owned, with just three license stores operated through a master franchise relationship with Alshaya Group in the Middle East. It had a footprint of 3,726 stores at the end of 2024, heavily indexed to the United States, although it maintains a small presence in Canada, the UK, France, and Germany. Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
<h3>Where Is Chipotle Mexican Grill Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,918,847, the CMG's price is up by 0.5%, now at $52.3. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 68 days.</li>
</ul>
<h3>What The Experts Say On Chipotle Mexican Grill</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $55.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Stephens &amp; Co. downgraded its action to Equal-Weight with a price target of $49. 
&#x2A; An analyst from Stephens &amp; Co. downgraded its action to Equal-Weight with a price target of $54. 
&#x2A; An analyst from Baird persists with their Outperform rating on Chipotle Mexican Grill, maintaining a target price of $56. 
&#x2A; Maintaining their stance, an analyst from TD Securities continues to hold a Buy rating for Chipotle Mexican Grill, targeting a price of $57. 
&#x2A; Consistent in their evaluation, an analyst from Loop Capital keeps a Buy rating on Chipotle Mexican Grill with a target price of $63. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Chipotle Mexican Grill options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Spotlight on Chipotle Mexican Grill: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in V usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Visa. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 25% bearish. Among these notable options, 5 are puts, totaling $254,725, and 3 are calls, amounting to $103,204.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $280.0 and $380.0 for Visa, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Visa stands at 844.29, with a total volume reaching 235.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Visa, situated within the strike price corridor from $280.0 to $380.0, throughout the last 30 days.
<h3>Visa Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747414984_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$21.95</td>
<td>$21.5</td>
<td>$21.83</td>
<td>$380.00</td>
<td>$100.8K</td>
<td>48</td>
<td align="right">67</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$19.15</td>
<td>$19.0</td>
<td>$19.0</td>
<td>$375.00</td>
<td>$51.3K</td>
<td>149</td>
<td align="right">27</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$22.35</td>
<td>$21.65</td>
<td>$21.99</td>
<td>$380.00</td>
<td>$46.1K</td>
<td>48</td>
<td align="right">21</td>
</tr>
<tr>
<td>V</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$45.75</td>
<td>$43.2</td>
<td>$45.08</td>
<td>$320.00</td>
<td>$36.0K</td>
<td>1.6K</td>
<td align="right">8</td>
</tr>
<tr>
<td>V</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$85.05</td>
<td>$85.05</td>
<td>$85.05</td>
<td>$280.00</td>
<td>$34.0K</td>
<td>312</td>
<td align="right">4</td>
</tr>
</tbody>
</table>

<h3>About Visa</h3>
Visa is the largest payment processor in the world. In fiscal 2023, it processed almost $15 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
After a thorough review of the options trading surrounding Visa, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Visa</h3>
<ul>
<li>Currently trading with a volume of 2,378,217, the V's price is up by 0.77%, now at $365.1. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 67 days.</li>
</ul>
<h3>Expert Opinions on Visa</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $384.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Visa, which currently sits at a price target of $380. 
&#x2A; Maintaining their stance, an analyst from Macquarie continues to hold a Outperform rating for Visa, targeting a price of $380. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Visa, maintaining a target price of $384. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Visa, targeting a price of $395. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Visa options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Visa's Options: A Look at What the Big Money is Thinking

Macro Economic Events

Econ #s

Economics

U.S. Baker Hughes Oil Rig Count -1 To 473; U.S. Baker Hughes NatGas Rig Count -1 To 100; U.S. Baker Hughes Total Rig Count 576 Vs 578 Prior

DELL

CNBC Halftime Report Final Trades: Dell Technologies, Boeing, UnitedHealth, QXO

CNBC Halftime Report Final Trades: Dell Technologies, Boeing, UnitedHealth Group, QXO

TAT Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) will release its quarterly earnings report on Monday, 2025-05-19. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate TAT Techs to report an earnings per share (EPS) of $0.31.
The announcement from TAT Techs is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Here's a look at TAT Techs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.3</td>
<td>0.26</td>
<td>0.25</td>
<td>0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>13.0%</td>
<td>17.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of TAT Techs were trading at $35.21 as of May 15. Over the last 52-week period, shares are up 157.45%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/TATT/earnings">To track all earnings releases for TAT Techs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TATT

Earnings Outlook For TAT Techs

Looking into the current session, Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) shares are trading at $166.78, after a 1.72% increase. Moreover, over the past month, the stock increased by 12.94%, but in the past year, decreased by 5.73%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747414844_0.png" alt="Past Year Chart" />

<h3>How Does Alphabet P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 31.27 in the Interactive Media &amp; Services industry, Alphabet Inc. has a lower P/E ratio of 18.3. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747414844_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

GOOGL

A Look Into Alphabet Inc's Price Over Earnings

Elon Musk <a href="https://ir.tesla.com/webcast-2025-01-29">acknowledged </a>in January that Tesla will need to replace Hardware 3 in vehicles owned by customers who purchased the Full Self-Driving package — a driver-assistance system marketed as capable of autonomous driving. He described the situation as both &#8220;painful&#8221; and &#8220;difficult.&#8221;
What was promised in 2016 is now being revised in 2025 — and not without surprises. Musk clarified that millions of Teslas built with Hardware 3 won't be able to reach full autonomy as initially planned.&nbsp;
Instead, they'll require an upgrade to Hardware 4, signaling a major shift from the company's earlier stance that Hardware 3 would be sufficient for FSD.
Don't Miss:
<ul class="wp-block-list">
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
<h2 class="wp-block-heading">Full Self-Driving Buyers Learn They're Not Quite There Yet</h2>
Tesla first claimed during a <a href="https://www.youtube.com/watch?v=FZ6lZJWL_Xk">press call</a> in October 2016 that all its vehicles came with the necessary hardware for full autonomy, encouraging drivers to purchase the FSD package—now priced as high as $15,000.&nbsp;
But during Tesla's<a href="https://www.youtube.com/watch?v=ScxNmPREZtg"> Q3 2024 earnings call</a> on Oct. 23, Musk publicly acknowledged that HW3's processing power is no longer sufficient for Tesla's evolving self-driving ambitions. He explained that achieving full autonomy—without driver supervision—requires far more computing power than initially expected.
Tesla is preparing to upgrade eligible vehicles free of charge. While this gesture may prevent legal blowback, it presents a new financial strain at a time when Tesla is already under pressure from slowing sales and tighter competition.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
<a href="https://electrek.co/2025/04/14/tesla-tsla-replace-computer-4-million-cars-or-compensate-their-owners">Electrek</a> estimated that over 4 million cars may be affected, which could cost Tesla hundreds of millions of dollars depending on retrofit demand. While the company did not confirm a figure, Musk referred to the financial impact as "non-trivial."
This isn't the first time Tesla has revised its hardware claims. <a href="https://mashable.com/article/tesla-elon-musk-hw3-fsd#:~:text=Tesla%20started%20shipping%20cars%20with%20HW3%20in,with%20HW4%20to%20enjoy%20its%20full%20benefits.">Mashable</a> reported that in 2019, owners of HW2 and HW2.5 vehicles were told they needed to upgrade to HW3 to continue using new FSD features. Now, five years later, the cycle is repeating with the transition to HW4.
Adding to the pressure, a <a href="https://www.teslaaction.com/">class-action lawsuit</a> filed in February alleges Tesla misled consumers by overstating its cars&#8217; self-driving capabilities. This latest hardware revelation could strengthen the plaintiffs' claims.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Meanwhile, competitors are charging ahead. According to <a href="https://www.theverge.com/tesla/654253/tesla-robotaxi-elon-musk-earnings-promise-fantasy">The Verge</a>, Waymo is completing over 200,000 driverless taxi rides per week using lidar and radar-based systems—components Tesla has consistently avoided in favor of a camera-only approach.
However, <a href="https://fortune.com/2025/04/23/tesla-elon-musk-warns-no-new-cars-coming-ai-and-robots-the-reality-is-the-future/">Fortune </a>reported that Tesla plans to debut its first supervised robotaxi fleet in Austin by mid-2025, starting with 10 to 20 Model Ys. But Musk cautioned that factors like weather may limit operations, undercutting earlier statements about achieving Level 5 autonomy in all conditions.
Tesla's EV market share in the U.S. dropped below 50% in early 2025, while European sales slumped amid growing competition.&nbsp;
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
</ul>
Image: Shutterstock

Elon Musk Calls It 'Painful And Difficult'—Why Tesla's Full Self-Driving Buyers May Need A Surprise Hardware Swap

Contracts

Press Releases

CleanCore Solutions, Inc. (ZONE) Launches Pilot Program with International Hotel Chain

CleanCore Solutions, Inc. (ZONE) Applauds EPA's Recent Ban of  Two Cancer-Causing Chemicals

CleanCore Solutions, Inc. (ZONE) Appoints Travis Buchanan as President

CleanCore Solutions, Inc. (ZONE) Launches Product Rollout at  Major International New York Airport

Momentum Stocks: PNPN.V, REBN, SOPA, KAVL, ZONE – Announcements Driving Growth

CleanCore Solutions, Inc. (ZONE) Reports Second Quarter FY 2025 Financial Results and Provides Business Update

CleanCore Solutions, Inc. (ZONE) Signs Definitive Agreement to Acquire Sanzonate Europe, the Largest Aqueous Ozone Product Distributor in Europe, Strengthening Financial Performance and Unlocking a Multi-Million Dollar Sales Pipeline

CleanCore Solutions, Inc. (ZONE) Completes Acquisition of Sanzonate Europe, Enhancing Leadership Position within the Industry

CleanCore Solutions, Inc. (ZONE) Approved by U.S. Government for Procurement with GSA Contract Award (MAS) Indefinite Delivery/Indefinite Quantity (IDIQ) Contract

CleanCore Solutions, Inc. (ZONE) Achieves 77.7% Year-Over-Year Revenue Growth for the Third Quarter of Fiscal 2025

KAVL

PNPNF

REBN

SOPA

TSXV:PNPN

ZONE

Nuburu

ClearSign Technologies Corporation - Common Stock

ClearSign Technologies

Chicago Rivet & Machine

Greenland Technologies Holding Corporation - Ordinary Shares

Greenland Technologies

Highway Holdings

Hurco Companies

INLIF

JE Cleantech Holdings Limited - Ordinary Shares

JE Cleantech Hldgs

Laser Photonics Corporation - Common Stock

Laser Photonics

Li Bang International Corporation Inc. - Ordinary Shares

Li Bang International

LiqTech International, Inc. - Common Stock

LiqTech International

Micropolis Holding Company Ordinary Shares

Micropolis Hldgs

Nephros

Rain Enhancement Technologies Holdco, Inc. - Class A Common Stock

Rain Enhancement

374Water

Techprecision

Screenshot 2024-10-11 at 5.37.42 PM

Emerging Markets

Movers & Shakers

CleanCore Solutions Announces String Of Wins Over Past Few Months, Including Deals With Fortune 50 Companies, Universities And More

Screenshot 2024-10-04 at 5.32.17 PM

How CleanCore (NYSEAMERICAN: ZONE) Is Helping Transform The Cleaning Industry Through Patented All-Natural Chemical-Free Solution

CleanCore Annual Results: Net Loss Narrowed, Gross Margins And Gross Profit Up After Shift In Sales Strategy, Company Reports Having 2 Years Runway Capital

Comments

CleanCore Solutions

ニュース

最新ニュース CleanCore Solutions (AMEX:ZONE) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル